MYCN and the epigenome

It is well known that Neuroblastoma (NB) patients whose tumors have an undifferentiated histology and a transcriptome enriched in cell cycle genes have a worse prognosis. This contrasts with the good prognoses of patients whose tumors have histologic evidence of differentiation and a transcriptome enriched in differentiation genes. Tumor cell lines from poor prognosis, high-risk patients contain a number of genetic alterations, including amplification of MYCN, 1pLOH, and unbalanced 11q or gains of Chr 17 and 7, and exhibit uncontrolled growth and an undifferentiated phenotype in in vitro culture. Yet treatment of such NB cell lines with retinoic acid results in growth control and induction of differentiation. This indicates that the signaling pathways that regulate cell growth and differentiation are not functionally lost but dysregulated. Agents such as retinoic acid normalize the signaling pathways and impose growth control and induction of differentiation. Recent studies in embryonic stem cells indicate that polycomb repressor complex proteins (PRC1 and PRC2) play a major role in regulating stem cell lineage specification and coordinating the shift from a transcriptome that supports self-renewal or growth to one that specifies lineage and controls growth. We have shown that in NB, the PRC2 complex is elevated in undifferentiated NB tumors and functions to suppress a number of tumor suppressor genes. This study will review the role of MYC genes in regulating the epigenome in normal development and explore how this role may be altered during tumorigenesis.

[1]  N. L. La Thangue,et al.  p300/CBP proteins: HATs for transcriptional bridges and scaffolds. , 2001, Journal of cell science.

[2]  Christopher B. Burge,et al.  c-Myc Regulates Transcriptional Pause Release , 2010, Cell.

[3]  C. Thiele,et al.  Selective Regulation of TrkA and TrkB Receptors by Retinoic Acid and Interferon-γ in Human Neuroblastoma Cell Lines (*) , 1995, The Journal of Biological Chemistry.

[4]  D. Stram,et al.  Histopathology (International Neuroblastoma Pathology Classification) and MYCN status in patients with peripheral neuroblastic tumors , 2001, Cancer.

[5]  Giacomo Finocchiaro,et al.  Myc-binding-site recognition in the human genome is determined by chromatin context , 2006, Nature Cell Biology.

[6]  C. Bustamante,et al.  Nucleosomal Elements that Control the Topography of the Barrier to Transcription , 2012, Cell.

[7]  P. Farnham,et al.  N-Myc regulates a widespread euchromatic program in the human genome partially independent of its role as a classical transcription factor. , 2008, Cancer research.

[8]  M. Cole,et al.  The Essential Cofactor TRRAP Recruits the Histone Acetyltransferase hGCN5 to c-Myc , 2000, Molecular and Cellular Biology.

[9]  William Arbuthnot Sir Lane,et al.  The c-MYC Oncoprotein Is a Substrate of the Acetyltransferases hGCN5/PCAF and TIP60 , 2004, Molecular and Cellular Biology.

[10]  Tom Misteli,et al.  The double bromodomain protein Brd4 binds to acetylated chromatin during interphase and mitosis , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[11]  Charles Y. Lin,et al.  Transcriptional Amplification in Tumor Cells with Elevated c-Myc , 2012, Cell.

[12]  Wen‐Ming Yang,et al.  Histone Deacetylases Associated with the mSin3 Corepressor Mediate Mad Transcriptional Repression , 1997, Cell.

[13]  R. Eisenman,et al.  Sin Meets NuRD and Other Tails of Repression , 1999, Cell.

[14]  C. Thiele,et al.  Epigenetic Changes in Pediatric Solid Tumors: Promising New Targets , 2012, Clinical Cancer Research.

[15]  R. Ferrari,et al.  Polycomb Repressive Complex 1 (PRC1) Disassembles RNA Polymerase II Preinitiation Complexes*♦ , 2012, The Journal of Biological Chemistry.

[16]  Lei Zeng,et al.  Structure and ligand of a histone acetyltransferase bromodomain , 1999, Nature.

[17]  Frank R. Lin,et al.  Opening of compacted chromatin by early developmental transcription factors HNF3 (FoxA) and GATA-4. , 2002, Molecular cell.

[18]  J. Carroll,et al.  Pioneer transcription factors: establishing competence for gene expression. , 2011, Genes & development.

[19]  P. Grant,et al.  NuA 4 , an essential transcription adaptor / histone H 4 acetyltransferase complex containing Esa 1 p and the ATM-related cofactor Tra 1 p , 2013 .

[20]  P. Grant,et al.  NuA4, an essential transcription adaptor/histone H4 acetyltransferase complex containing Esa1p and the ATM‐related cofactor Tra1p , 1999, The EMBO journal.

[21]  D. Livingston,et al.  MYC recruits the TIP60 histone acetyltransferase complex to chromatin , 2003, EMBO reports.

[22]  D. Green,et al.  c-Myc Is a Universal Amplifier of Expressed Genes in Lymphocytes and Embryonic Stem Cells , 2012, Cell.

[23]  D. Ayer,et al.  Histone deacetylases: transcriptional repression with SINers and NuRDs. , 1999, Trends in cell biology.

[24]  J. Trent,et al.  Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour , 1983, Nature.

[25]  E. Lander,et al.  The Mammalian Epigenome , 2007, Cell.

[26]  M. Cole,et al.  Myc Regulation of mRNA Cap Methylation. , 2010, Genes & cancer.

[27]  Stuart H. Orkin,et al.  A Myc Network Accounts for Similarities between Embryonic Stem and Cancer Cell Transcription Programs , 2010, Cell.

[28]  J. Maris,et al.  Outcome of high‐risk stage 3 neuroblastoma with myeloablative therapy and 13‐cis‐retinoic acid: A report from the Children's Oncology Group , 2009, Pediatric blood & cancer.

[29]  Dean W. Felsher,et al.  Cellular senescence is an important mechanism of tumor regression upon c-Myc inactivation , 2007, Proceedings of the National Academy of Sciences.

[30]  M. Cole,et al.  The Novel ATM-Related Protein TRRAP Is an Essential Cofactor for the c-Myc and E2F Oncoproteins , 1998, Cell.

[31]  J. Khan,et al.  EZH 2 Mediates Epigenetic Silencing of Neuroblastoma Suppressor Genes CASZ 1 , CLU , RUNX 3 , and NGFR , 2011 .

[32]  Guillaume J. Filion,et al.  Systematic Protein Location Mapping Reveals Five Principal Chromatin Types in Drosophila Cells , 2010, Cell.

[33]  R. Young,et al.  BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc , 2011, Cell.

[34]  S. McMahon,et al.  Metastasis-associated protein 1 (MTA1) is an essential downstream effector of the c-MYC oncoprotein. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[35]  Michael D. Cole,et al.  Transcription-independent functions of MYC: regulation of translation and DNA replication , 2008, Nature Reviews Molecular Cell Biology.

[36]  M. Cole,et al.  An ATPase/helicase complex is an essential cofactor for oncogenic transformation by c-Myc. , 2000, Molecular cell.

[37]  H. Ding,et al.  Direct effects of Bmi1 on p53 protein stability inactivates oncoprotein stress responses in embryonal cancer precursor cells at tumor initiation , 2013, Oncogene.

[38]  Robert E. Kingston,et al.  Mechanisms of Polycomb gene silencing: knowns and unknowns , 2009, Nature Reviews Molecular Cell Biology.

[39]  Christopher J. Ott,et al.  BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. , 2012, Blood.

[40]  L. Larsson,et al.  Combined IFN-γ and retinoic acid treatment targets the N-Myc/Max/Mad1 network resulting in repression of N-Myc target genes in MYCN-amplified neuroblastoma cells , 2007, Molecular Cancer Therapeutics.

[41]  Greg Donahue,et al.  Facilitators and Impediments of the Pluripotency Reprogramming Factors' Initial Engagement with the Genome , 2012, Cell.

[42]  K. Dahlman-Wright,et al.  Functional interaction of the c-Myc transactivation domain with the TATA binding protein: evidence for an induced fit model of transactivation domain folding. , 1996, Biochemistry.

[43]  S. G. Cheng,et al.  c-MYC interacts with INI1/hSNF5 and requires the SWI/SNF complex for transactivation function , 1999, Nature Genetics.

[44]  M. Kimura,et al.  Bmi1 is a MYCN target gene that regulates tumorigenesis through repression of KIF1Bβ and TSLC1 in neuroblastoma , 2010, Oncogene.

[45]  R. Rosenfeld.  Nature , 2009, Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery.

[46]  J. Khan,et al.  EZH2 Mediates epigenetic silencing of neuroblastoma suppressor genes CASZ1, CLU, RUNX3, and NGFR. , 2012, Cancer research.

[47]  Hongjuan Cui,et al.  Bmi-1 is essential for the tumorigenicity of neuroblastoma cells. , 2007, The American journal of pathology.

[48]  F. Setién,et al.  The tumour suppressor and chromatin-remodelling factor BRG1 antagonizes Myc activity and promotes cell differentiation in human cancer , 2012, EMBO molecular medicine.

[49]  M. Israel,et al.  Decreased expression of N-myc precedes retinoic acid-induced morphological differentiation of human neuroblastoma , 1985, Nature.

[50]  Sharon Y. R. Dent,et al.  N-Myc and GCN5 Regulate Significantly Overlapping Transcriptional Programs in Neural Stem Cells , 2012, PloS one.

[51]  Jan Koster,et al.  Functional MYCN signature predicts outcome of neuroblastoma irrespective of MYCN amplification , 2012, Proceedings of the National Academy of Sciences.

[52]  B. Lüscher,et al.  Stimulation of c‐MYC transcriptional activity and acetylation by recruitment of the cofactor CBP , 2003, EMBO reports.

[53]  S. Oliviero,et al.  Myc Regulates the Transcription of the PRC2 Gene To Control the Expression of Developmental Genes in Embryonic Stem Cells , 2011, Molecular and Cellular Biology.

[54]  David Horn,et al.  Histone deacetylases. , 2008, Advances in experimental medicine and biology.

[55]  T. Mahmoudi,et al.  Conserved P-TEFb-interacting domain of BRD4 inhibits HIV transcription , 2007, Proceedings of the National Academy of Sciences.

[56]  Philip R. Gafken,et al.  Myc influences global chromatin structure , 2006, The EMBO journal.

[57]  H. Varmus,et al.  Definition of regions in human c-myc that are involved in transformation and nuclear localization , 1987, Molecular and cellular biology.

[58]  F. Alt,et al.  N-myc can functionally replace c-myc in murine development, cellular growth, and differentiation. , 2000, Genes & development.

[59]  G. Perini,et al.  A SP1/MIZ1/MYCN repression complex recruits HDAC1 at the TRKA and p75NTR promoters and affects neuroblastoma malignancy by inhibiting the cell response to NGF. , 2011, Cancer research.

[60]  C. Allis,et al.  The language of covalent histone modifications , 2000, Nature.

[61]  G. D. Valle,et al.  Molecular and Cellular Pathobiology A SP 1 / MIZ 1 / MYCN Repression Complex Recruits HDAC 1 at the TRKA and p 75 NTR Promoters and Affects Neuroblastoma Malignancy by Inhibiting the Cell Response to NGF , 2011 .

[62]  B. Howard,et al.  The Transcriptional Coactivators p300 and CBP Are Histone Acetyltransferases , 1996, Cell.